Abstract
β-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on β-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.
Similar content being viewed by others
References and Recommended Reading
Hunt SA, American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005, 46:e1–e82.
Fonarow GC, ADHERE Scientific Advisory Committee: The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003, 4(Suppl 7):S21–30.
Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 343:1349–1355.
Franciosa JA, Massie BM, Lukas MA, et al.: β-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J 2004, 148:718–726.
Ko DT, Hebert PR, Coffey CS, et al.: Adverse effects of β-blocker therapy for patients with HF: a quantitative overview of randomized trials. Arch Intern Med 2004, 164:1389–1394.
Gattis WA, O’Connor CM, Gallup DS, et al.: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol 2004, 43:1534–1541.
Spaeder JA, Najjar SS, Gerstenblith G, et al.: Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. Am Heart J 2006, 151:844.e1–e10.
Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312–2318.
Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057.
Shakar SF, Abraham WT, Gilbert WM, et al.: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory Class IV heart failure. J Am Coll Cardiol 1998, 31:1336–1340.
Kumar A, Choudhary G, Antonio C, et al.: Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001, 142:512–515.
Epstein SE, Braunwald E: The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Ann Intern Med 1966, 65:20–27.
Weil JV, Chidsey CA: Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation 1968, 37:54–61.
Packer M, Coats AJS, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.
Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001–2007.
A randomized trial of beta-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees. Circulation 1994, 90:1765–1773.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9–13.
Beta-blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659–1667.
Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000, 101:378–384.
Gilbert EM, Abraham WT, Olsen S, et al.: Comparative hemodynamic, left ventricular functional, and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996, 94:2817–2825.
Nul D, Zambrano C, Diaz A, et al.: Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovasc Drugs Ther 2005, 18:125–134.
Wilkoff BL, Cook JR, Epstein AE, et al.: Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA 2002, 288:3115–3123.
Stecker EC, Fendrick M, Knight BP, Aaronson KD: Prophylactic pacemaker use to allow β-blocker therapy in patients with chronic HF with bradycardia. Am Heart J 2006, 151:820–828.
Heart Failure Society of America: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006, 12:e1–2.
Zewail AM, Nawar M, Vrtovec B, et al.: Intravenous milrinone in the treatment of advanced congestive HF. Tex Heart Inst J 2003, 30:109–113.
McKelvie RS, Teo KK, McCartney N, et al.: Effects of exercise training in patients with congestive HF: a critical review. J Am Coll Cardiol 1995, 25:789–796.
Coats AJS, Adamopoulos S, Radaelli A, et al.: Controlled trial of physical training in chronic HF: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992, 85:2119–2131.
Jónsdóttir S, Andersen KK, Sigurðsson AF, Sigurðsson SB: The effect of physical training in chronic HF. Eur J Heart Fail 2006, 8:97–101.
Forissier JF, Vernochet P, Bertrand P, et al.: Influence of carvedilol on the benefits of physical training in patients with moderate chronic HF. Eur J Heart Fail 2001, 3:335–342.
Kukin ML, Kalman J, Charney RH, et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99:2645–2651.
Ko DT, Hebert PR, Coffey CS, et al.: β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002, 288:351–357.
Lue TF: Drug therapy: erectile dysfunction. N Engl J Med 2000, 342:1802–1813.
Katz SD, Parker JD, Glasser DB, et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005, 95:36–42.
Salpeter SR, Ormiston TM, Salpeter EE, et al.: Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Resp Med 2003, 97:1094–1101.
Camsari A, Arikan S, Avan C, et al.: Metoprolol, a β1-selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003, 18:188–192.
Barnett MJ, Milavetz G, Kaboli PJ: β-blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy 2005, 25:1550–1559.
Kotlyar E, Keogh AM, Macdonald PS, et al.: Tolerability of carvedilol in patients with HF and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transpl 2002, 21:1290–1295.
LeJemtel TH, Padeletti M, Jelic S: Diagnostic and therapeutic challenges in patients with coexistent and chronic obstructive pulmonary disease and congestive HF. J Am Coll Cardiol 2007, 49:171–180.
Vale JA, Van de Pette SJ, Price TML: Peripheral gangrene complicating beta-blockade. Lancet 1977, 2:412.
Vale JA, Jefferys DB: Peripheral gangrene complicating beta-blockade. Lancet 1978, 1:1216.
Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A: Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987, 2:650–653.
Hiatt WR, Stoll S, Nies AS: Effect of β-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985, 72:1226–1231.
Radack K, Deck C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991, 151:1769–1776.
Ubbink DT, Verhaar EE, Lie HK, Legamate DA: Effect of β-blockers on peripheral skin microcirculation in hypertension and peripheral arterial disease. J Vasc Surg 2003, 38:535–540.
Hirsch AT, Haskal ZJ, Hertzer NR: ACC/AHA guidelines for the management of patients with peripheral arterial disease. J Am Coll Cardiol 2005, 47:1239–1312.
Mendelson G, Aronow WS: Underutilization of beta-blockers in older patients with prior myocardial infarction or coronary artery disease in an academic, hospital-based geriatrics practice. J Am Geriatric Soc 1997, 45:1360–1361.
Sinha S, Goldstein M, Penrod J, et al.: Brief report: β-blocker use among veterans with systolic HF. J Gen Intern Med 2006, 21:1306–1309.
Deedwania P, Gottlieb S, Ghali JK, et al.: Efficacy, safety, and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004, 25:1300–1309.
Hülsmann M, Berger R, Mörtl D, Pacher R: Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart failure survey. Eur J Heart Fail 2005, 7:657–661.
Lawless CE, Tamlyn T, Shah R, et al.: Titration of carvedilol in elderly HF patients. Am J Geriatr Cardiol 2005, 14:230–235.
Wikstrand J, Hjalmarson A, Waagstein F, et al.: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002, 40:491–498.
Gress TW, Nieto J, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342:905–912.
Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes and hypertension: a randomized controlled trial. JAMA 2004, 292:2227–2236.
Deedwania PC, Giles TD, Klibaner M, et al.: Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005, 149:159–167.
Bell DS, Lukas MA, Holdbrook FK, Fowler MB: The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006, 22:287–296.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsai, S., Klapholz, M. Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure. Curr Heart Fail Rep 4, 110–116 (2007). https://doi.org/10.1007/s11897-007-0009-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-007-0009-2